Literature DB >> 12087064

Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size.

Nicole S Wayman1, Yoshiyuki Hattori, Michelle C McDonald, Helder Mota-Filipe, Salvatore Cuzzocrea, Babrbara Pisano, Prabal K Chatterjee, Christoph Thiemermann.   

Abstract

This study was designed to investigate the effects of various chemically distinct activators of PPAR-gamma and PPAR-alpha in a rat model of acute myocardial infarction. Using Northern blot analysis and RT-PCR in samples of rat heart, we document the expression of the mRNA for PPAR-gamma (isoform 1 but not isoform 2) as well as PPAR-beta and PPAR-alpha in freshly isolated cardiac myocytes and cardiac fibroblasts and in the left and right ventricles of the heart. Using a rat model of regional myocardial ischemia and reperfusion (in vivo), we have discovered that various chemically distinct ligands of PPAR-gamma (including the TZDs rosiglitazone, ciglitazone, and pioglitazone, as well as the cyclopentanone prostaglandins 15D-PGJ2 and PGA1) cause a substantial reduction of myocardial infarct size in the rat. We demonstrate that two distinct ligands of PPAR-alpha (including clofibrate and WY 14643) also cause a substantial reduction of myocardial infarct size in the rat. The most pronounced reduction in infarct size was observed with the endogenous PPAR-gamma ligand, 15-deoxyDelta12,14-prostagalndin J2 (15D-PGJ2). The mechanisms of the cardioprotective effects of 15D-PGJ2 may include 1) activation of PPAR-alpha, 2) activation of PPAR-gamma, 3) expression of HO-1, and 4) inhibition of the activation of NF-kappaB in the ischemic-reperfused heart. Inhibition by 15D-PGJ2 of the activation of NF-kappaB in turn results in a reduction of the 1) expression of inducible nitric oxide synthase and the nitration of proteins by peroxynitrite, 2) formation of the chemokine MCP-1, and 3) expression of the adhesion molecule ICAM-1. We speculate that ligands of PPAR-gamma and PPAR-alpha may be useful in the therapy of conditions associated with ischemia-reperfusion of the heart and other organs. Our findings also imply that TZDs and fibrates may help protect the heart against ischemia-reperfusion injury. This beneficial effect of 15D-PGJ2 was associated with a reduction in the expression of the 1) adhesion molecules ICAM-1 and P-selectin, 2) chemokine macrophage chemotactic protein 1, and 3) inducible isoform of nitric oxide synthase. 15D-PGJ2 reduced the nitration of proteins (immunohistological analysis of nitrotyrosine formation) caused by ischemia-reperfusion, likely due to the generation of peroxynitrite. Not all of the effects of 15D-PGJ2, however, are due to the activation of PPAR-gamma. For instance, exposure of rat cardiac myocytes to 15D-PGJ2, but not to rosiglitazone, results in an up-regulation of the expression of the mRNA for heme-oxygenase-1 (HO-1). Taken together, these results provide convincing evidence that several, chemically distinct ligands of PPAR-gamma reduce the tissue necrosis associated with acute myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12087064     DOI: 10.1096/fj.01-0793com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  77 in total

1.  Postnatal rosiglitazone administration to neonatal rat pups does not alter the young adult metabolic phenotype.

Authors:  Nghia C Truong; Afshan Abbasi; Reiko Sakurai; W N Paul Lee; John S Torday; Virender K Rehan
Journal:  Neonatology       Date:  2011-11-10       Impact factor: 4.035

2.  Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1.

Authors:  Qing Qing Wu; Yanxia Wang; Martin Senitko; Colin Meyer; W Christian Wigley; Deborah A Ferguson; Eric Grossman; Jianlin Chen; Xin J Zhou; John Hartono; Pamela Winterberg; Bo Chen; Anapam Agarwal; Christopher Y Lu
Journal:  Am J Physiol Renal Physiol       Date:  2011-02-02

3.  A role of PPAR-gamma in androstenediol-mediated salutary effects on cardiac function following trauma-hemorrhage.

Authors:  Tomoharu Shimizu; László Szalay; Ya-Ching Hsieh; Takao Suzuki; Mashkoor A Choudhry; Kirby I Bland; Irshad H Chaudry
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

Review 4.  Involvement of PPAR nuclear receptors in tissue injury and wound repair.

Authors:  Liliane Michalik; Walter Wahli
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

Review 5.  Peroxisome proliferator-activated receptors ligands and ischemia-reperfusion injury.

Authors:  Rosanna Di Paola; Salvatore Cuzzocrea
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-03-13       Impact factor: 3.000

6.  Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.

Authors:  Salvatore Cuzzocrea; Barbara Pisano; Laura Dugo; Angela Ianaro; Nimesh S A Patel; Rosanna Di Paola; Tiziana Genovese; Prabal K Chatterjee; Massimo Di Rosa; Achille P Caputi; Christoph Thiemermann
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

Review 7.  Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists.

Authors:  Ramya Kapadia; Jae-Hyuk Yi; Raghu Vemuganti
Journal:  Front Biosci       Date:  2008-01-01

8.  15-deoxy-Delta12,14 prostaglandin J2-induced heme oxygenase-1 in megakaryocytes regulates thrombopoiesis.

Authors:  J J O'Brien; C J Baglole; T M Garcia-Bates; N Blumberg; C W Francis; R P Phipps
Journal:  J Thromb Haemost       Date:  2008-10-10       Impact factor: 5.824

9.  Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction.

Authors:  Stefan Frantz; Kai Hu; Julian Widder; Barbara Bayer; Catharina Clara Witzel; Isabel Schmidt; Paolo Galuppo; Jörg Strotmann; Georg Ertl; Johann Bauersachs
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

10.  Effects of 15-deoxy-Delta12,14-prostaglandin-J2 during hyperdynamic porcine endotoxemia.

Authors:  Balázs Hauser; Jochen Kick; Zsolt Iványi; Pierre Asfar; Ulrich Ehrmann; Claus-Martin Muth; Maura Albicini; Ulrich Wachter; Josef Vogt; Michael Bauer; Uwe Bernd Brückner; Peter Radermacher; Hendrik Bracht
Journal:  Intensive Care Med       Date:  2006-03-14       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.